Main Industry
Health Care
Main Product/Service
1. Botanical Drug Active Substance Screening Platform
2. GACP Cultivation Philosophy and Plantation Planning
3. Botanical New Drug R&D: Alzheimer's Disease Drug (AD1)
(The content above was translated by AI.)
2. GACP Cultivation Philosophy and Plantation Planning
3. Botanical New Drug R&D: Alzheimer's Disease Drug (AD1)
(The content above was translated by AI.)
Founded Year
2011
Unified Business No.
53437018
Status
Active
Number of Employees
0
Total Paid-in
Capital
278,111,510 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
B&V BIOPHARMA CO., LTD. is a company focusing on the research and development of botanical new drugs, with over 80% of its talent pool consisting of master's and doctoral degree holders. Currently, the company's core botanical new drug is for Alzheimer's disease. The company has commissioned Taiwan EPS Health Care Bio-tech Consulting Co., Ltd., a CRO (Contract Research Organization) under Japan's ITOCHU Group, to submit an IND (Investigational New Drug) application for Phase II clinical trials in Taiwan. The targeted therapeutic population is patients with early-stage Alzheimer's disease, utilizing a botanical new drug compound and a multi-target therapeutic approach to prevent and treat neuropathy.
The company's business plan is mainly divided into three phases. In the short term, active substances are screened through a botanical drug active substance screening platform; on one hand, this can be used for the development and licensing of nutritional supplements and botanical essential oils, and on the other hand, it serves as targets for future new drug development. In the medium term, raw material specifications are standardized through GACP (Good Agricultural and Collection Practice) cultivation base planning technology; on one hand, this allows for the cultivation of B&V BIOPHARMA CO., LTD.'s own medicinal raw material plants, and on the other hand, it can also accept contract cultivation commissioned by other new drug companies. The long-term ultimate goal is the research and development of botanical new drugs, thereby generating milestone payments and sales royalties through the company's drug development.
In its future development, B&V BIOPHARMA CO., LTD. will focus on two areas: botanical new drug research and development, and administrative management. For the subsequent stages of botanical new drug R&D, the company will continue its technical cooperation with the Development Center for Biotechnology; as for administrative management, KPMG is currently providing planning and guidance for internal audits and internal controls, as well as financial and tax auditing services, as the company continues to plan and move toward the goal of an IPO (Initial Public Offering).
(The content above was translated by AI.)
The company's business plan is mainly divided into three phases. In the short term, active substances are screened through a botanical drug active substance screening platform; on one hand, this can be used for the development and licensing of nutritional supplements and botanical essential oils, and on the other hand, it serves as targets for future new drug development. In the medium term, raw material specifications are standardized through GACP (Good Agricultural and Collection Practice) cultivation base planning technology; on one hand, this allows for the cultivation of B&V BIOPHARMA CO., LTD.'s own medicinal raw material plants, and on the other hand, it can also accept contract cultivation commissioned by other new drug companies. The long-term ultimate goal is the research and development of botanical new drugs, thereby generating milestone payments and sales royalties through the company's drug development.
In its future development, B&V BIOPHARMA CO., LTD. will focus on two areas: botanical new drug research and development, and administrative management. For the subsequent stages of botanical new drug R&D, the company will continue its technical cooperation with the Development Center for Biotechnology; as for administrative management, KPMG is currently providing planning and guidance for internal audits and internal controls, as well as financial and tax auditing services, as the company continues to plan and move toward the goal of an IPO (Initial Public Offering).
(The content above was translated by AI.)
